1. A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer.
- Author
-
Cetin, Metin, Saatci, Ozge, Rezaeian, Abdol-Hossein, Rao, Chintada Nageswara, Beneker, Chad, Sreenivas, Kukkamudi, Taylor, Harrison, Pederson, Breanna, Chatzistamou, Ioulia, Buckley, Brian, Lessner, Susan, Angel, Peggi, McInnes, Campbell, and Sahin, Ozgur
- Abstract
Lysyl oxidase (LOX) is upregulated in highly stiff aggressive tumors, correlating with metastasis, resistance, and worse survival; however, there are currently no potent, safe, and orally bioavailable small molecule LOX inhibitors to treat these aggressive desmoplastic solid tumors in clinics. Here we discovered bi-thiazole derivatives as potent LOX inhibitors by robust screening of drug-like molecules combined with cell/recombinant protein-based assays. Structure-activity relationship analysis identified a potent lead compound (LXG6403) with ∼3.5-fold specificity for LOX compared to LOXL2 while not inhibiting LOXL1 with a competitive, time- and concentration-dependent irreversible mode of inhibition. LXG6403 shows favorable pharmacokinetic properties, globally changes ECM/collagen architecture, and reduces tumor stiffness. This leads to better drug penetration, inhibits FAK signaling, and induces ROS/DNA damage, G1 arrest, and apoptosis in chemoresistant triple-negative breast cancer (TNBC) cell lines, PDX organoids, and in vivo. Overall, our potent and tolerable bi-thiazole LOX inhibitor enhances chemoresponse in TNBC, the deadliest breast cancer subtype. [Display omitted] • A cell-based HTS identifies bi-thiazole derivatives as potent LOX inhibitors • LXG6403 is a well-tolerated potent LOX inhibitor with favorable drug-like features • LXG6403 rewires collagen architecture/signaling to overcome chemoresistance in TNBC • LXG6403 is a promising lead candidate for highly stiff drug resistant tumors Cetin-Saatci et al. identified a potent and well-tolerated bi-thiazole LOX inhibitor LXG6403, overcoming chemoresistance in TNBC, the deadliest breast cancer subtype, by rewiring collagen architecture/signaling and increasing drug penetration. LXG6403 has great potential for optimization for future clinical testing in LOX-driven diseases, including chemoresistant TNBC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF